Literature DB >> 16611189

Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.

S Chainuvati1, S K Khalid, S Kancir, M Shea, J Edwards, M Sernyak, S Wongcharatrawee, G Garcia-Tsao.   

Abstract

Hepatitis C virus (HCV) infection is more frequent in veterans than in nonveterans. Up to 85% of HCV-infected veterans have psychiatric and/or substance use (SU) co-morbidities which, prior to the 2002 NIH Consensus Conference, were considered relative contraindications to antiviral therapy, assuming a poor adherence. With the objective of evaluating the validity of this assumption, we compared eligibility, completion and response to antiviral therapy in HCV-infected veterans with and without these comorbidities. Veterans who were anti-HCV-positive and had been seen at least once in the liver clinic (between October 1999 and June 2002) were identified through the CT-VAHCS database. Records were reviewed for patient demographics and status of liver disease, assessment of treatment eligibility, type of therapy, completion of therapy and virological response. Patients with active mental illness (MI) or SU were compared with those without these comorbidities (controls). Of 697 anti-HCV-positive-patients, 647 HCV-RNA-positive patients were included, 294 with MI/SA and 353 controls. Patient demographics, viral and liver disease characteristics were comparable between groups. Patients with MI/SA were considered ineligible for therapy more frequently (53%vs 39%, P < 0.001) and were treated less frequently (21%vs 28%, P = 0.03) than controls. However, completion of therapy (72%vs 59%) and sustained virological response (SVR) (20%vs 25%) did not differ significantly between groups. HCV-infected veterans with MI/SA are being offered therapy and treated less often than those without such co-morbidities, however therapy completion and SVR rates are similar, challenging the perception that adherence is poorer in this patient population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611189     DOI: 10.1111/j.1365-2893.2005.00681.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  12 in total

1.  Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia.

Authors:  Marilyn Huckans; Alex Mitchell; Samantha Ruimy; Jennifer Loftis; Peter Hauser
Journal:  Schizophr Bull       Date:  2008-06-17       Impact factor: 9.306

2.  Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment.

Authors:  Steven L Batki; Kelly M Canfield; Robert Ploutz-Snyder
Journal:  Am J Addict       Date:  2011-05-31

3.  Provider Perceptions of Hepatitis C Treatment Adherence and Initiation.

Authors:  Grace Zhang; Krupa Patel; Akshata Moghe; Andrea Reid; Marina Serper; Linda Calgaro; Sandra Gibson; Susan Zickmund; Obaid Shaikh; Shari Rogal
Journal:  Dig Dis Sci       Date:  2019-10-23       Impact factor: 3.199

4.  Primary Care and Hepatology Provider-Perceived Barriers to and Facilitators of Hepatitis C Treatment Candidacy and Adherence.

Authors:  Shari S Rogal; Rory McCarthy; Andrea Reid; Keri L Rodriguez; Linda Calgaro; Krupa Patel; Molly Daley; Naudia L Jonassaint; Susan L Zickmund
Journal:  Dig Dis Sci       Date:  2017-05-18       Impact factor: 3.199

5.  Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection.

Authors:  Glenn Wagner; Gery Ryan; Karen Chan Osilla; Laveeza Bhatti; Matthew Goetz; Mallory Witt
Journal:  AIDS Patient Care STDS       Date:  2009-09       Impact factor: 5.078

6.  Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence.

Authors:  Peter Higgs; Rachel Sacks-Davis; Judy Gold; Margaret Hellard
Journal:  Hepat Mon       Date:  2011-07       Impact factor: 0.660

Review 7.  Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

Authors:  Mark S Sulkowski; Curtis Cooper; Bela Hunyady; Jidong Jia; Pavel Ogurtsov; Markus Peck-Radosavljevic; Mitchell L Shiffman; Cihan Yurdaydin; Olav Dalgard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

8.  Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder.

Authors:  Peter Hauser; Benjamin J Morasco; Alex Linke; Dannell Bjornson; Samantha Ruimy; Annette Matthews; Aly Rifai; David W Indest; Jennifer M Loftis
Journal:  Psychosomatics       Date:  2009 Sep-Oct       Impact factor: 2.386

Review 9.  Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications.

Authors:  Peter Hauser; Shira Kern
Journal:  World J Hepatol       Date:  2015-07-28

10.  Acceptability of psychotherapy, pharmacotherapy, and self-directed therapies in Australians living with chronic hepatitis C.

Authors:  Benjamin J R Stewart; Deborah Turnbull; Antonina A Mikocka-Walus; Hugh A J Harley; Jane M Andrews
Journal:  J Clin Psychol Med Settings       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.